Explore our range of useful resources, designed to support you with your decision making. You can download the files to refer to later.

For ENTRESTO® (sacubitril/valsartan) prescribing information click here

For Inclisiran▼ (Leqvio®) prescribing information click here

 

Preview of NHS Scotland Heart Failure Transition and Recovery Plan in response to COVID-19 (25th May 2020)

NHS Scotland Heart Failure Transition and Recovery Plan in response to COVID-19 (25th May 2020)

Download the key recommendations from the Heart Failure Hub Scotland to ensure a sustainable model of care for heart failure patients during the COVID-19 pandemic, as we move into the recovery phase of the plan.

Download resource

Preview of CaReMe algorithm for chronic heart failure management

CaReMe algorithm for chronic heart failure management

Download the management algorithm for chronic heart failure in adults from CaReMe UK, 2021.

Download resource

 

Preview of JACC treatment algorithm for guideline-directed medical therapy including novel therapies

JACC treatment algorithm for guideline-directed medical therapy including novel therapies

Download the treatment algorithm for the management of patients with chronic heart failure with reduced ejection fraction, from the Journal of the American College of Cardiology (JACC).

Download resource

Preview of Bradford Pathway for the Management of Heart Failure with Left Ventricular Systolic Dysfunction (LVSD)

Bradford Pathway for the Management of Heart Failure with Left Ventricular Systolic Dysfunction (LVSD)

Download the Bradford Pathway for the management of heart failure with LVSD.

Download resource

 

Preview of Inclisiran formulary application pack

Inclisiran formulary application pack

Information intended to support you with your local formulary submission for Inclisiran.

Registration is required to access this resource.

Download resource

Preview of NICE Guidance on Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

NICE Guidance on Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Technology appraisal guidance [TA733] from NICE.

This document contains links which will take you to external websites over which Novartis Pharmaceuticals UK Limited has no ownership or control. Novartis Pharmaceuticals UK Limited accepts no responsibility for the content, accuracy, or your use of linked websites.

View full guidance

 

Preview of SMC guidance on the use of Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

SMC guidance on the use of Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Inclisiran is accepted for restricted use within NHS Scotland in adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, as monotherapy or in combination with lipid-lowering therapies.

This document contains links which will take you to external websites over which Novartis Pharmaceuticals UK Limited has no ownership or control. Novartis Pharmaceuticals UK Limited accepts no responsibility for the content, accuracy, or your use of linked websites.

View full guidance

 

If you would like to find out more, please search NHS futures.

 

JACC, Journal of the American College of Cardiology; LVSD, left ventricular systolic dysfunction; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

Rate this content: 
No votes yet
UK | February 2022 | 118739-2
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]